La Jolla exits to Innoviva in a deal that caps 33 years marked by misses in lupus, malaria and beta thalassemia – Endpoints News

Business News

1. La Jolla exits to Innoviva in a deal that caps 33 years marked by misses in lupus, malaria and beta thalassemia  Endpoints News
2. Struggling La Jolla sells out to Innoviva for $149M  FiercePharma
3. La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News  InvestorPlace

Source: Business News